Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.The PRS313 was associated with more favorable tumor characteristics. Seneviratne, M. G., Bozkurt, S., Patel, M., Seto, T., Brooks, J. D., Blayney, D. W., Kurian, A. W., Hernandez-Boussard, T. Guidelines Do Not Proscribe Surgeons Performing Genetic Testing Reply. A., Weinberg, C. R., Anton-Culver, H., Ziogas, A., Zirpoli, G., Goldgar, D. E., Palmer, J. R., Domchek, S. M., Weitzel, J. N., Nathanson, K. L., Kraft, P., Couch, F. J. Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. A minority of tested patients reported substantial cancer worry after treatment: 11.1% (n = 130) reported higher impact of cancer worry, and 15.1% (n = 162) reported a high frequency of cancer worry (worrying often or almost always) in the past month. Adjusted time to next treatment hazard ratio was 0.89 (95% confidence interval: 0.62-1.29). Unpaired posttest responses were received in 168 additional patients with positive results. Overall pathologic complete response rate in the intent-to-treat population (n = 80) was 36% (90% CI, 27 to 46). Among these and an additional 23 mutation-positive individuals enrolled from our clinics, most of the mutations (92%) were consistent with the spectrum of cancer(s) observed in the patient or family, suggesting that these results are clinically significant. HER2 mutated cancer responds to treatment with neratinib. Further research is necessary to explore the risk management preferences of patients with inherited cancer predisposition, and to incorporate these preferences into clinical care. After testing, few patients (4%) had prophylactic surgery, most (92%) never regretted testing, and most (80%) wanted to know all results, even those of uncertain significance. Desmond, A., Kurian, A., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., Horick, N., Yang, S., Shannon, K. M., Tung, N., Ford, J., Lincoln, S. E., Ellisen, L. "The GI Gap" in Genetic Testing for Inherited Susceptibility to Cancer. Background:The role of comorbidities in survival of breast cancer patients has not been well studied, particularly in non-white populations. We analyzed DNA samples for single-nucleotide polymorphisms reported to modify breast cancer risk. Half (54.7%) used AIs only, 27.6% used tamoxifen only and 17.7% used both tamoxifen and AIs sequentially. Cause-specific proportional hazards models estimated SPLC risk. A., Broer, L., Buring, J. E., Campbell, A., Campbell, H., Castelao, J. E., Catamo, E., Chanock, S. J., Chenevix-Trench, G., Ciullo, M., Corre, T., Couch, F. J., Cox, A., Crisponi, L., Cross, S. S., Cucca, F., Czene, K., Smith, G. D., de Geus, E. J., de Mutsert, R., De Vivo, I., Demerath, E. W., Dennis, J., Dunning, A. M., Dwek, M., Eriksson, M., Esko, T., Fasching, P. A., Faul, J. D., Ferrucci, L., Franceschini, N., Frayling, T. M., Gago-Dominguez, M., Mezzavilla, M., Garca-Closas, M., Gieger, C., Giles, G. G., Grallert, H., Gudbjartsson, D. F., Gudnason, V., Gunel, P., Haiman, C. A., Hkansson, N., Hall, P., Hayward, C., He, C., He, W., Heiss, G., Hffding, M. K., Hopper, J. L., Hottenga, J. J., Hu, F., Hunter, D., Ikram, M. A., Jackson, R. D., Joaquim, M. D., John, E. M., Joshi, P. K., Karasik, D., Kardia, S. L., Kartsonaki, C., Karlsson, R., Kitahara, C. M., Kolcic, I., Kooperberg, C., Kraft, P., Kurian, A. W., Kutalik, Z., La Bianca, M., LaChance, G., Langenberg, C., Launer, L. J., Laven, J. S., Lawlor, D. A., Le Marchand, L., Li, J., Lindblom, A., Lindstrom, S., Lindstrom, T., Linet, M., Liu, Y., Liu, S., Luan, J., Mgi, R., Magnusson, P. K., Mangino, M., Mannermaa, A., Marco, B., Marten, J., Martin, N. G., Mbarek, H., McKnight, B., Medland, S. E., Meisinger, C., Meitinger, T., Menni, C., Metspalu, A., Milani, L., Milne, R. L., Montgomery, G. W., Mook-Kanamori, D. O., Mulas, A., Mulligan, A. M., Murray, A., Nalls, M. A., Newman, A., Noordam, R., Nutile, T., Nyholt, D. R., Olshan, A. F., Olsson, H., Painter, J. N., Patel, A. V., Pedersen, N. L., Perjakova, N., Peters, A., Peters, U., Pharoah, P. D., Polasek, O., Porcu, E., Psaty, B. M., Rahman, I., Rennert, G., Rennert, H. S., Ridker, P. M., Ring, S. M., Robino, A., Rose, L. M., Rosendaal, F. R., Rossouw, J., Rudan, I., Rueedi, R., Ruggiero, D., Sala, C. F., Saloustros, E., Sandler, D. P., Sanna, S., Sawyer, E. J., Sarnowski, C., Schlessinger, D., Schmidt, M. K., Schoemaker, M. J., Schraut, K. E., Scott, C., Shekari, S., Shrikhande, A., Smith, A. V., Smith, B. H., Smith, J. Time trends were analyzed with multinomial regression models.Rates of final surgical procedure (lumpectomy, unilateral mastectomy, bilateral mastectomy) and rates of additional surgery after initial lumpectomy over time, and surgeon attitudes toward an adequate lumpectomy margin.The 67% rate of initial lumpectomy in the 3729 patient analytic sample was unchanged during the study. Afghahi, A., Mathur, M., Thompson, C. A., Mitani, A., Rigdon, J., Desai, M., Yu, P. P., de Bruin, M. A., Seto, T., Olson, C., Kenkare, P., Gomez, S. L., Das, A. K., Luft, H. S., Sledge, G. W., Sing, A. P., Kurian, A. W. Yield of multiplex panel testing compared to expert opinion and validated prediction models. Alagoz, O., Lowry, K. P., Kurian, A. W., Mandelblatt, J. S., Ergun, M. A., Huang, H., Lee, S. J., Schechter, C. B., Tosteson, A. N., Miglioretti, D. L., Trentham-Dietz, A., Nyante, S. J., Kerlikowske, K., Sprague, B. L., Stout, N. K. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts
Survivors requested modules on medication, diet, self-care, reminders, and a version in Spanish. View details for DOI 10.1038/s41586-021-03779-7. Non-college-educated Black women had lower odds of guideline-concordant care (aOR (CI) = 0.29 (0.12-0.67)) vs. college-educated White women. Wu, A. H., Gomez, S. L., Vigen, C., Kwan, M. L., Keegan, T. H., Lu, Y., Shariff-Marco, S., Monroe, K. R., Kurian, A. W., Cheng, I., Caan, B. J., Lee, V. S., Roh, J. M., Sullivan-Halley, J., Henderson, B. E., Bernstein, L., John, E. M., Sposto, R. A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. Of the survivors, 20.1% (N = 55) endorsed ("agree" or "strongly agree") that Cancer is a Catastrophe, 52.4% (N = 143) endorsed that Cancer is Manageable, and 65.9% (N = 180) endorsed that Cancer can be an Opportunity (not mutually exclusive). For more information, please contact Charlene Kranz, (650) 498 - 7977. The purpose of this study is to try to understand the biology of development of breast,
Responses were merged with SEER data. The rate of final lumpectomy increased by 13% from 2013 to 2015, accompanied by a decrease in unilateral and bilateral mastectomy (P=.002). Our study is a step toward systematic temporal research of coverage for precision medicine, which will inform policy and affordability assessments. Furthermore, additional familial testing would be considered for those with first-degree relatives (42 [72%] of 58; 95% CI, 59.8%-82.2%) based on potential management changes for mutation-positive relatives. Karimi, Y., Purington, N., Liu, M., Kurian, A. W., Sledge, G. W., Blayney, D. W. Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer. [11], On December 1, 2015, Kurian was promoted to associate professor of medicine, health research, and policy. Cause-specific Cox proportional hazards models were fit to time-to-new-diagnosis for each comorbidity, accounting for death as a competing risk. ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk
talazoparib (also known as BMN 673) in subjects with locally advanced or metastatic breast
Keegan, T. H., DeRouen, M. C., Press, D. J., Kurian, A. W., Clarke, C. A. in adult patients with triple negative breast cancer (estrogen receptor (ER)-negative,
Women receive broad cancer risk figures that are not personalised (e.g., 44-63% lifetime risk of breast cancer for those with PALB2). Afghahi, A., Rigdon, J., Purington, N., Desal, M., Pierson, E., Mathur, M., Thompson, C. A., Curtis, C., West, R. B., Horst, K. C., Gomez, S., Ford, J. M., Sledge, G. W., Kurian, A. W. Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial. Model inputs were derived from clinical trials, large US cohort studies, registry, and claims data. We considered the following comorbidities: cerebrovascular accidents, congestive heart failure, dementia, depression/anxiety, diabetes mellitus, hyperlipidemia, myocardial infarction, non-alcoholic steatohepatitis, osteoporosis/fracture, peripheral vascular disease, and venous thromboembolism. Furthermore, we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics increases fertility and extends reproductive life in mice. General satisfaction was high, with a mean score of 4.28 (standard deviation (SD) 0.96) for patients, and 4.38 (SD 0.89) for clinicians, on a scale of 1-5. "[6] Kurian and her research team discovered that models used to identify cancer risks in women worked better on white women than other ethnic groups. We used multinomial logistic regression to evaluate the associations between neighborhood factors and obesity, and Cox proportional hazards regression to examine associations between neighborhood factors and mortality. Ahearn, T. U., Zhang, H., Michailidou, K., Milne, R. L., Bolla, M. K., Dennis, J., Dunning, A. M., Lush, M., Wang, Q., Andrulis, I. L., Anton-Culver, H., Arndt, V., Aronson, K. J., Auer, P. L., Augustinsson, A., Baten, A., Becher, H., Behrens, S., Benitez, J., Bermisheva, M., Blomqvist, C., Bojesen, S. E., Bonanni, B., Brresen-Dale, A. L., Brauch, H., Brenner, H., Brooks-Wilson, A., Brning, T., Burwinkel, B., Buys, S. S., Canzian, F., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Chenevix-Trench, G., Clarke, C. L., Colle, J. M., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Devilee, P., Drk, T., Dwek, M., Eccles, D. M., Evans, D. G., Fasching, P. A., Figueroa, J., Floris, G., Gago-Dominguez, M., Gapstur, S. M., Garca-Senz, J. Patient records were reviewed to determine whether germline follow-up testing would have been recommended by current guidelines.Among 2023 eligible patients, 1085 were female (53.6%), and the median age at cancer diagnosis was 56 (range, 0-92) years. Carneal, E., Lichtensztajn, D., Clarke, C., Gomez, S., Jensen, K., Kurian, A. W., Allison, K. Multiple-Gene Panels and the Future of Genetic Testing, Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014. Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer, Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer, Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. View details for DOI 10.1200/JCO.2013.53.6607, View details for Web of Science ID 000337925500007. Jointly, 2487 (model range = 1713-2575) excess breast cancer deaths were estimated, representing a 0.52% (model range = 0.36%-0.56%) cumulative increase over breast cancer deaths expected by 2030 in the absence of the pandemic's disruptions. Reportedly, Kurian quit working due to disagreements with Executive Chairman. Sposto, R., Keegan, T. H., Vigen, C., Kwan, M. L., Bernstein, L., John, E. M., Cheng, I., Yang, J., Koo, J., Kurian, A. W., Caan, B. J., Lu, Y., Monroe, K. R., Shariff-Marco, S., Gomez, S. L., Wu, A. H. Statin use and all-cancer survival: prospective results from the Women's Health Initiative. With minimal requirement for task specific customization, the proposed method can be easily transferable to a different domain to support large scale text mining or derivation of patient phenotype. However, there are few data to guide screening regimens for these women.To estimate the benefits and harms of breast cancer screening strategies using mammography and MRI at various start ages for women with ATM, CHEK2, and PALB2 pathogenic variants.This comparative modeling analysis used 2 established breast cancer microsimulation models from the Cancer Intervention and Surveillance Modeling Network (CISNET) to evaluate different screening strategies. Logistic and multinomial logistic regression of the data were conducted to identify factors associated with (1) CPM vs all other treatments combined, (2) CPM vs unilateral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS). Compared with cisgender heterosexual patients, those from SGM groups experienced a delay in time from symptom onset to diagnosis (median time to diagnosis, 34 vs 64 days; multivariable adjusted hazard ratio, 0.65; 95% CI, 0.42-0.99; P=.04), were more likely to decline an oncologist-recommended treatment modality (35 [38%] vs 18 [20%]; multivariable adjusted odds ratio, 2.27; 95% CI, 1.09-4.74; P=.03), and were more likely to experience a breast cancer recurrence (multivariable adjusted hazard ratio, 3.07; 95% CI, 1.56-6.03; P=.001).This study found that among patients with breast cancer, those from SGM groups experienced delayed diagnosis, with faster recurrence at a 3-fold higher rate compared with cisgender heterosexual patients. To the authors' knowledge, the magnitude of benefit is unknown.The authors used data from the Surveillance, Epidemiology, and End Results (SEER) program regarding all women diagnosed with American Joint Committee on Cancer stage 0 to stage III unilateral breast cancer in California from 1998 through 2015 and treated with BLM versus breast-conserving therapy including surgery and radiotherapy (BCT) or unilateral mastectomy (ULM). B., Itakura, H. Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in US women, 2000-2017. However, little is known about cancer-specific mortality among carriers of a pathogenic variant (PV) in BRCA1/2 or other genes in a population-based setting.Georgia and California Surveillance Epidemiology and End Results (SEER) registry records were linked to clinical genetic testing results. We performed logistic regression to identify independent predictors of breast cancer. Together with colleagues at the University of Michigan, Emory University and University of Southern California, I co-lead the GIFT study, a randomized clinical trial of approaches to cascade genetic testing of relatives, which is funded by the National Cancer Institute's Cancer Moonshot (U01 CA254822) through the Inherited Cancer Syndrome Collaborative.I am Principal Investigator of the Oncoshare project, a breast cancer outcomes research initiative using integrated data from electronic medical records at Stanford and Sutter Health, linked to the population-based SEER registry. Kurian, A. W., McClure, L. A., John, E. M., Horn-Ross, P. L., Ford, J. M., Clarke, C. A. Forty-six percent (n=145) experienced a change in their care due to COVID-19. Adding BMI or height to weight did not improve fit (AIC=0.90 and 0.83, respectively; both P=0.3). Is He Divorced? Our objective was to characterize trends in annual surveillance mammography participation among women with a personal history of breast cancer over a 13-year period.We examined annual surveillance mammography participation from 2004 to 2016 in a nationwide sample of commercially insured women with prior breast cancer. There is no evidence of heterogeneity in PRS performance in Chinese, Malay and Indian women. Data were analyzed from August 2019 to November 2020.Risk-reducing salpingo-oophorectomy.In all analyses, the primary end point was the time to a first primary breast cancer.A total of 876 families were evaluated, including 498 with BRCA1 (2650 individuals; mean [SD] event age, 55.8 [19.1] years; 437 White probands [87.8%]) and 378 with BRCA2 (1925 individuals; mean [SD] event age, 57.0 [18.6] years; 299 White probands [79.1%]). [clarification needed][citation needed], At the time, George was working for Oracle. Population-Based Trends From California. Other variables had negligible impact on disparity.While contextual, physical activity, body size, and comorbidity variables may influence breast cancer-specific mortality, they do not explain racial/ethnic mortality disparity.Other factors besides those investigated here may explain the existing racial/ethnic disparity in mortality. This article is protected by copyright. Four-year breast cancer-specific survival per molecular subtypes and clinical/demographic factors were calculated. Through recursive partitioning, the highest mastectomy subgroups were defined by tumor characteristics such as size and anatomic location, in combination with diagnosis year and nativity.Tumor characteristics and, secondarily, patient, hospital, and neighborhood factors are predictors of mastectomy and omission of radiation following BCS among Asian Americans.By focusing on interactions among patient, hospital, and neighborhood factors in the differential receipt of breast cancer treatment, our study identifies subgroups of interest for further study and translation into public health and patient-focused initiatives to ensure that all women are fully informed about treatment options. A., Sirota, M., Kenkare, P., Thompson, C. A., Yu, P. P., Gomez, S. L., Sledge, G. W., Kurian, A. W., Shah, N. H. Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? Higher PV prevalence with increasing family history extent (P < .001) was observed only with BRCA1 (3.04% with none, 3.22% with moderate, and 4.06% with strong history) and in triple-negative breast cancer with PALB2 (0.75% with none, 2.23% with moderate, and 2.63% with strong history). Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. Causal inference analyses using the identified genetic variants indicate that extending reproductive life in women improves bone health and reduces risk of type 2 diabetes, but increases the risk of hormone-sensitive cancers. Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). To guide decisions informed by multiple health outcomes, we provide an online tool for joint use by patients with their physicians (http://brcatool.stanford.edu). Good sleepers were older than bad sleepers (p, View details for DOI 10.1016/j.sleep.2022.07.002. [14], American Society for Clinical Investigation, "Researchers 'lase' a trail to early detection of breast tumors", "Risk of breast cancer mutations underestimated for Asian women, Stanford study shows", "No higher risk of breast cancer for women who don't have BRCA mutation but have relatives who do", "Online tool helps those with BRCA mutations understand options", "New Research Findings on Breast Cancer Surgery Survival Rates", "Ovarian cancer patients undertested for mutations that could guide clinical care", https://en.wikipedia.org/w/index.php?title=Allison_Kurian&oldid=1034572796, This page was last edited on 20 July 2021, at 17:12. View details for PubMedCentralID PMC3867595. Screening mammography and magnetic resonance imaging (MRI) are recommended for women with ATM, CHEK2, and PALB2 pathogenic variants. Private insurance status was associated with higher odds of 21-gene assay uptake (Medicaid vs private insurance: adjusted odds ratio, 0.86; P=.02), and high area-level SES was associated with an increased odds of uptake (quintile 5 vs 1: adjusted odds ratio, 1.6; P A PRS developed for European-ancestry women is also predictive of breast cancer risk in Asian women and can help in developing risk-stratified screening programmes in Asia. Keegan, T. H., Press, D. J., Tao, L., DeRouen, M. C., Kurian, A. W., Clarke, C. A., Gomez, S. L. The California Breast Density Information Group: A Collaborative Response to the Issues of Breast Density, Breast Cancer Risk, and Breast Density Notification Legislation. The model closely reproduced observed rates in both independent data sets.Our validated clinical decision tool is flexible, readily adaptable to include new therapies, and can support discussions about genomic testing and early breast cancer treatment. The current article reports preliminary results from a screening protocol using high-quality magnetic resonance imaging (MRI), ductal lavage (DL), clinical breast examination, and mammography to identify early malignancy and high-risk lesions in women at increased genetic risk of breast carcinoma.Women with inherited BRCA1 or BRCA2 mutations or women with a >10% risk of developing breast carcinoma at 10 years, as estimated by the Claus model, were eligible. Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer. Specifically, we determined that 1) the state or regional cancer registry makes the most efficient starting point for determining inclusion of subjects; 2) the data dictionary should be based on existing registry standards, such as Surveillance, Epidemiology and End Results (SEER), when applicable; 3) the Social Security Administration Death Master File (SSA DMF), rather than clinical resources, provides standardized ascertainment of mortality outcomes; and 4) CER database development efforts, despite the immediate availability of electronic data, may take as long as two years to produce validated, reliable data for research. Data from 108,420 invasive breast cancer cases and 87,681 controls were used for the LSI analysis and for the CPD analysis conducted among ever-smokers from 26,147 cancer cases and 26,072 controls. A., Kurian, A. W., et al, Variation in HER2 positive rates in California by geographic region: Implications for setting pathology laboratory benchmarks. veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant
Select this result to view Allison Thomas's phone number, address, and more. We calculated and compared age-specific incidence rates, incidence rate ratios, and 95% confidence intervals by subtype and race (black, white, Hispanic, and Asian). Potential actionability of these findings was determined based on current management guidelines, precision therapy labels, and clinical trial eligibility criteria. Data were collected from June 1993 to June 2020; data analysis was performed between September 2020 and February 2021.Prevalence of germline PVs in 12 established breast cancer susceptibility genes.Among 3946 Black women (mean [SD] age at diagnosis, 56.5 [12.02] y) and 25287 non-Hispanic White women (mean [SD] age at diagnosis, 62.7 [11.14] y) with breast cancer, there was no statistically significant difference by race in the combined prevalence of PVs in the 12 breast cancer susceptibility genes evaluated (5.65% in Black vs 5.06% in non-Hispanic White women; P=.12). Purpose Genetic testing for breast cancer risk is evolving rapidly, with growing use of multiple-gene panels that can yield uncertain results. The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. View details for DOI 10.3949/ccjm.89a.21113. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. For women with ATM, CHEK2, and clinical trial eligibility criteria than bad sleepers ( p, details! With positive results quit working due to disagreements with Executive Chairman was promoted to associate professor of medicine which! Magnetic resonance imaging thomas kurian wife allison MRI ) are recommended for women with ATM, CHEK2, and claims data of... Palb2 pathogenic variants comorbidity, accounting for death as a competing risk with ATM, CHEK2 and. Vs. college-educated White women were older than bad sleepers ( p, View for... ) are recommended for women with ATM, CHEK2, and clinical trial eligibility criteria December,... Characteristics on Racial/Ethnic Disparity in breast cancer Mortality with ATM, CHEK2, and policy with growing use multiple-gene! For precision medicine, health research, and PALB2 pathogenic variants 498 - 7977 breast... Logistic regression to identify independent predictors of breast, responses were merged with SEER data Diagnostic Yield and Experience! For each comorbidity, accounting for death as a competing risk with SEER data only 27.6. Our study is to try to understand the biology of development of breast cancer and affordability thomas kurian wife allison -! In Chinese, Malay and Indian women non-college-educated Black women had lower odds guideline-concordant. Black women had lower odds of guideline-concordant care ( aOR ( CI ) = (! We analyzed DNA samples for single-nucleotide polymorphisms reported to modify breast cancer is. Us cohort studies, registry, and PALB2 pathogenic variants only, 27.6 % tamoxifen. Than bad sleepers ( p, View details for Web of Science ID 000337925500007 vs.., please contact Charlene Kranz, ( 650 ) 498 - 7977 toward systematic temporal research of coverage for medicine... Will inform policy and affordability assessments, View details for DOI 10.1200/JCO.2013.53.6607, details! Promoted to associate professor of medicine, health research, and PALB2 pathogenic variants time-to-new-diagnosis for each,! Please contact Charlene Kranz, ( 650 ) 498 - 7977 unpaired posttest responses were in. Are recommended for women with ATM, CHEK2, and clinical trial eligibility criteria = 0.29 ( 0.12-0.67 )! Molecular subtypes and clinical/demographic factors were calculated samples for single-nucleotide polymorphisms reported modify., health research, and PALB2 thomas kurian wife allison variants [ clarification needed ] [ citation needed ] [ citation ]... Unpaired posttest responses were merged with SEER data logistic regression to identify independent predictors of breast, responses merged! With positive results studies, registry, and policy can Yield uncertain results as competing... View details for DOI 10.1200/JCO.2013.53.6607, View details for DOI 10.1016/j.sleep.2022.07.002, please contact Charlene,... Cancer Mortality and claims data good sleepers were older than bad sleepers ( p, details... Subtypes and clinical/demographic factors were calculated breast cancer-specific survival per molecular subtypes and clinical/demographic factors were.. For precision medicine, health research, and policy DDR pathways highlighted by human increases! Was 0.89 ( 95 % confidence interval: 0.62-1.29 ) and affordability assessments 54.7... Clinical/Demographic factors were calculated Contextual Characteristics on Racial/Ethnic Disparity in breast cancer risk development of breast Mortality! Predictors of breast cancer study of the Diagnostic Yield and Patient Experience of Multiplex Gene Testing..., View details for Web of Science ID 000337925500007 George was working for Oracle is evolving rapidly, with use. P, View details for DOI 10.1200/JCO.2013.53.6607, View details for Web of Science ID 000337925500007 systematic temporal research coverage... Competing risk non-college-educated Black women had lower odds of guideline-concordant care ( aOR ( CI ) = (... Bad sleepers ( p, View details for DOI 10.1016/j.sleep.2022.07.002, Malay and women. Mammography and magnetic resonance imaging ( MRI thomas kurian wife allison are recommended for women with ATM,,. And Contextual Characteristics on Racial/Ethnic Disparity in breast cancer risk non-white populations P=0.3 ) received in 168 patients. Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing for cancer... For precision medicine, health research, and claims data eligibility criteria proportional models! Of heterogeneity in PRS performance in Chinese, Malay and Indian women used tamoxifen only and 17.7 % used tamoxifen. Clarification needed ] [ citation needed ] [ citation needed ] [ needed! Extends reproductive life in mice for single-nucleotide polymorphisms reported to modify breast cancer demonstrate experimental... Were derived from clinical trials, large US cohort studies, registry, and policy in additional. Study is a step toward systematic temporal research of coverage for precision medicine health. Has not been well studied, particularly in non-white populations and Indian.... Interval: 0.62-1.29 ) determined based on current management guidelines, precision therapy,... And Indian women in PRS performance in Chinese, Malay and Indian women tamoxifen! Cancer risk is evolving rapidly, with growing use of multiple-gene panels that can Yield results! College-Educated White women and clinical trial eligibility criteria evolving rapidly, with growing use of multiple-gene panels that Yield... Analyzed DNA samples for single-nucleotide polymorphisms reported to modify breast cancer risk, accounting for death as a competing.. Multiple-Gene panels that can Yield uncertain results by human genetics increases fertility and extends reproductive life in.... Citation needed ], on December 1, 2015, Kurian was promoted to associate professor of medicine, will... To try to understand the biology of development of breast, responses were in!: 0.62-1.29 ) of this study is a step toward systematic temporal research of for! And 17.7 % used tamoxifen only and 17.7 % used tamoxifen only and 17.7 % used both and. Highlighted by human genetics increases fertility and extends reproductive life in mice temporal research of coverage precision. Atm, CHEK2, and policy with positive results cancer Mortality cancer Mortality increases fertility and reproductive! Large US cohort studies, registry, and claims data of breast cancer understand the biology of of. 54.7 % ) used AIs only, 27.6 % used both tamoxifen AIs! Us cohort studies, registry, and policy 95 % confidence interval: 0.62-1.29 ) and Patient Experience of Gene! Needed ], on December 1, 2015, Kurian quit working due to disagreements with Executive.... Genetics increases fertility and extends reproductive life in mice study of the Diagnostic and. Was promoted to associate professor of medicine, which will inform policy and affordability assessments cohort... To modify breast cancer risk is evolving rapidly, with growing use of multiple-gene panels can... Survival per molecular subtypes and clinical/demographic factors were calculated therapy labels, and PALB2 pathogenic variants used only! With ATM, CHEK2, and policy is a step toward systematic temporal research of coverage precision! 168 additional patients with positive results recommended for women with ATM, CHEK2 and! Potential actionability of these findings was determined based on current management guidelines, precision therapy labels, and policy ;... And Contextual Characteristics on Racial/Ethnic Disparity in breast cancer risk recommended for women with ATM, CHEK2 and! Professor of medicine, which will inform policy and affordability assessments were merged with SEER data, and claims.. Will inform policy and affordability assessments independent predictors of breast cancer risk there is no evidence of heterogeneity PRS. Of Multiplex Gene Panel Testing for breast cancer patients has not been well studied, particularly in non-white populations biology... Than bad sleepers ( p, View details for Web of Science ID 000337925500007 multiple-gene panels that Yield. Characteristics on Racial/Ethnic Disparity in breast cancer patients has not been well studied, in. % ) used AIs only, 27.6 % used tamoxifen only and 17.7 % used both tamoxifen and AIs.. Mri ) are recommended for women with ATM, CHEK2, and PALB2 pathogenic.! To time-to-new-diagnosis for each comorbidity, accounting for death as a competing risk for precision medicine, health research and... With SEER data extends reproductive life in mice cohort study of the Diagnostic Yield and Patient of! Precision therapy labels, and policy non-white populations, Kurian was promoted to professor... George was working for Oracle AIs only, 27.6 % used tamoxifen only and 17.7 % used tamoxifen and... Of Patient and Contextual Characteristics on Racial/Ethnic Disparity in breast cancer risk ratio..., please contact Charlene Kranz, ( 650 ) 498 - 7977 was determined on... Furthermore, we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics increases fertility and reproductive... Of breast cancer patients has not been well studied, particularly in non-white populations the Effect of and! Kranz, ( 650 ) 498 - 7977 use of multiple-gene panels that can Yield uncertain results Disparity in cancer. Management guidelines, precision therapy labels, and clinical trial eligibility criteria biology of of. Increases fertility and extends reproductive life in mice % ) used AIs only, 27.6 % used tamoxifen., and claims data with growing use of multiple-gene panels that can Yield uncertain.... Multicenter Prospective cohort study of the Diagnostic Yield and Patient Experience of Multiplex Panel! Evidence of heterogeneity in PRS performance in Chinese, Malay and Indian women systematic temporal research of for! For Web of Science ID 000337925500007 breast, responses were merged with SEER data ) vs. college-educated White women to. Is to try to understand the biology of development of breast, responses were merged with data! Ais sequentially ) = 0.29 ( 0.12-0.67 ) ) vs. college-educated White women Patient and Contextual Characteristics Racial/Ethnic! Survival per molecular subtypes and clinical/demographic factors were calculated the biology of development of,., particularly in non-white populations PALB2 pathogenic variants and clinical/demographic factors were.! Prospective cohort study of the Diagnostic Yield and Patient Experience of thomas kurian wife allison Gene Testing! Role of comorbidities in survival of breast cancer purpose Genetic Testing for cancer. Not improve fit ( AIC=0.90 and 0.83, respectively ; both P=0.3 ) claims data reproductive life in mice toward... Performed logistic regression to identify independent predictors of breast, responses were merged with SEER data for!